AccessibilityHelpAbout Us
Biostax logo

Biostax(OTC) IMUN

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year+0%
1 Month+100%
N/A
Biostax last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-09
Biostax stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+100%USD 0.002026-08-14
1 month+100%USD 0.002026-08-07
3 month+100%USD 0.002026-06-09
Year to date+100%USD 0.002025-12-30
1 year+0%USD 0.002025-08-05
3 year-99.93%USD 0.282023-09-07
5 year-99.99%USD 3.002021-09-10
Since inception-100%USD 5,100.002012-05-14

Biostax Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$934.00K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

IMUN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biostax

Immune Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for various medical conditions. The company, formerly known as TNI BioTech, Inc., is headquartered in Orlando, Florida, and has undergone significant changes since adopting its current name in 2014.

Products and Services
  • Development of immunotherapy treatments for autoimmune diseases
  • Research initiatives aimed at enhancing patient outcomes
  • Collaboration with healthcare professionals for clinical trials
Growth Outlook
  • Recent strategic initiatives aim to expand product pipeline
  • Potential partnerships could enhance research capabilities
  • Focus on innovative therapies aligns with market demand
Financial Highlights
  • Quarterly operating expenses totaled $288,466 in Q2 2024
  • Trailing twelve months (TTM) net income shows a significant loss
  • Market capitalization stands at approximately $7.78 million
Immune Therapeutics, Inc. currently does not conduct significant business operations, which may raise concerns for potential investors. The company has reported no revenue in recent quarters, indicating a need for strategic direction and operational focus. The recent quarterly financials show a notable increase in operating expenses, which could impact cash flow and overall financial health. Despite these challenges, the company is positioned in a growing sector, with increasing interest in immunotherapy and biotechnology solutions. The focus on innovative therapies and potential collaborations may provide avenues for future growth. Investors may find the company's strategic initiatives and market positioning worth monitoring as developments unfold.
AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Noreen M. Griffin

Website

www.biostaxcorp.com

Headquarters

Winter Park, FL 32792, US

IMUN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

67.11%

Return on Capital

N/A

Return on Assets

-6695.90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$840.00K

EBITDA

$812.78K

Operating Cash Flow

-$153.42K

Capital Expenditure

$0.00

Free Cash Flow

-$153.42K

Cash & ST Invst.

-$49.00

Total Debt

$1.17M

Biostax Performance Analysis

Biostax annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Biostax sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
Biostax annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.38N/A
20222022-12-31USD -0.10N/A
20232023-12-31USD -0.03-70.9%
Biostax sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3022.5%
Q42023-12-31400.0%
Q12024-03-31-100.0%
Q22024-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$0.00

+100.0%

EBITDA

$0.00

+100.0%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

-$49.00

-100.0%

Total Debt

$1.17M

+68.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.17M

+68.0%

Return on Assets

-66.96%

N/A

Return on Invested Capital

32.80%

N/A

Free Cash Flow

$11.06K

+102.5%

Operating Cash Flow

$11.06K

+102.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
POLXFPolydex Pharmaceuticals Limited
$1.99+0.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About IMUN

What is the current price of Biostax?

Biostax is trading at N/A per share.

What is the 52-week range for Biostax?

Over the past 52 weeks, Biostax has traded between N/A and N/A.

How much debt does Biostax have?

As of the most recent reporting period, Biostax reported total debt of $1.16M.

How much cash does Biostax have on hand?

Biostax reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Biostax’s dividend yield?

Biostax does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services